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Small Malignant Hepatic Tumor
Detection in Gadolinium- and
Ferucarbotran-Enhanced Magnetic
Resonance Imaging: does Combining
Ferucarbotran-Enhanced T2*-Weighted
Gradient Echo and T2-Weighted Turbo
Spin Echo Images have Additive Efficacy? 
Objective: To determine if a combination of ferucarbotran-enhanced
T2*weighted-gradient echo (T2*W-GRE) and T2-weighted turbo spin echo (T2W-
TSE) images in gadolinium- and ferucarbotran-enhanced MRI has additive effica-
cy compared to each image alone for detecting small (≤ 2.0 cm) hepatocellular
carcinoma (HCC) lesions in a group of cirrhotic patients and metastases in a
group of non-cirrhotic patients.
Materials and Methods: Two readers retrospectively analyzed gadolinium-
and ferucarbotran-enhanced T2*W-GRE, T2W-TSE, and combined T2*W-
GRE/T2W-TSE images of 119 patients with 157 HCCs and 32 patients with 98
metastases. The diagnostic accuracy and sensitivity for each image set and the
combined set were evaluated using the alternative-free response receiver operat-
ing characteristic method.  
Results: The mean area under the curve value of the combined set (0.966)
tended to be better than that for each individual image set (T2W-TSE [0.910],
T2*W-GRE [0.892]). Sensitivities in the combined set were higher than those in
each individual image set for detecting HCC (mean, 93.0% versus 81.6% and
86.7%, respectively, p < 0.01). Sensitivities in the combined set and the T2W-
TSE set were the same for detecting metastases, and both were higher than the
sensitivity seen in the T2*W-GRE set (mean, 97.5% versus 85.2 %, p < 0.01). 
Conclusion: Combining ferucarbotran-enhanced T2*W-GRE and T2W-TSE
has additive efficacy for detecting HCC in cirrhotic patients, but T2W-TSE is pre-
ferred for detecting metastases in non-cirrhotic patients. 
ith the recent development of tissue-specific MR contrast agents such as
superparamagnetic iron oxide (SPIO) and gadobenate dimeglumine, it is
widely agreed that contrast-enhanced liver MR is the most accurate non-
invasive imaging modality for the evaluation of liver malignancies, including hepato-
cellular carcinoma (HCC) and metastases (1-3). The combined use of gadolinium and
SPIO is recommended to increase accuracy in the detection and characterization of
focal liver lesions and is considered the most accurate non-invasive imaging modality
for the evaluation of liver tumors (4, 5). 
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WSuperparamagnetic iron oxide-enhanced MR imaging has
received attention as a non-invasive examination to
replace CT arterial portography for the detection of liver
malignancies (3, 6). Extensive studies have been conducted
to determine the optimal pulse sequence for SPIO-
enhanced MRI. Although debate still exists, T2*-weighted
gradient recalled-echo (T2*W-GRE) and T2-weighted
turbo-spin echo (T2W-TSE) sequences have been most
widely used as optimized sequences in SPIO-enhanced
MRI for the detection of focal liver lesions (7-10).
However, in spite of the variety of pulse sequences now
available for SPIO-enhanced liver MRI in clinical practice,
there is no published data concerning the question of
whether T2*W-GRE or T2W-TSE sequences alone in
SPIO-enhanced MRI are sufficient for the detection of liver
malignancies, or if the sequences should be combined to
provide better detection. Considering the acquisition of
multiple MR sequences can be time-consuming and can
result in greater inconvenience to patients (particularly
when double contrast MRI is considered), acquisition of
objective data regarding the use of combined sequences in
SPIO-enhanced MRI is reasonable. Therefore, this study
was conducted to determine if combining SPIO-enhanced
T2*W-GRE and T2W-TSE sequences in sequentially
acquired gadolinium-enhanced and SPIO-enhanced MRI
has additive value compared to each sequence alone, for
the detection of small liver malignancies, including HCCs
and metastases. Additionally, we wanted to analyze the
relative efficacy of each MR sequence and both sequences
combined, with regard to HCCs in patients with underly-
ing chronic liver disease and liver metastases in patients
with no underlying liver disease. This study was conducted
in a large series of patients.
MATERIALS AND METHODS
Patients 
We retrospectively reviewed our institutional database
for liver MRIs conducted between January 2004 and
September 2006 on patients suspected of having liver
malignancy based on clinical and prior CT findings. We
identified 391 patients with HCCs and 55 patients with
liver metastases who underwent a double contrast MRI
that consisted of a sequentially acquired gadolinium-
enhanced and ferucarbotran-enhanced liver MRI. No
institutional review board approval was required for
retrospective review of medical records and images.
Of the 446 potential study patients, only those who met
the following criteria were included in the study: (a)
nodular HCC 2 cm or smaller in size that had been proven
on histology or showed typical imaging findings on hepatic
angiography, Lipiodol CT, and dynamic CT, (b) liver
metastases 2 cm or smaller in size that had been proven on
histology or showed typical imaging findings on three-
phase dynamic CT and follow-up CT or MRI (rapid
progression of disease), (c) follow-up contrast-enhanced CT
or MRI performed for at least six months (range: 6-30
months). Consequently, the study population included 151
patients (114 men and 37 women; age range: 40-74 years):
119 patients with 157 HCCs and 32 patients with 98
metastases. The lesion distribution according to the confir-
mative diagnostic method is given in Table 1. Of 51 HCCs
(from 38 patients) that were confirmed by pathologic
analysis of surgical specimens, 45 lesions were grade I (n =
15) or II (n = 30) according to Edmondson’s classification
of HCC (11), and the remaining six were grade III. For the
81 patients with 106 HCCs who underwent transarterial
chemoembolization, the final diagnosis was based on a
combined interpretation of findings from all diagnostic
procedures by two experienced radiologists in consensus.
Diagnostic procedures included the following: image-
guided biopsy (n = 12), characteristic imaging findings on
three-phase multidetector CT (MDCT) and MRI (arterial
hypervascularization and early washout on dynamic
imaging and arterial hypervascularization plus hyperinten-
sity on SPIO-enhanced MRI) (n = 106), and persistent
dense compact nodular Lipiodol uptake of the detected
lesions on MDCT and MRI after TACE (n = 106) (12), as
well as aggravation (local recurrence or new growing
HCCs) on follow-up CT or MRI (n = 19). Of all the patients
with HCCs, four underwent ablation therapy, and two
underwent chemoembolization before MRI. All patients
with HCCs had liver cirrhosis (n = 116) or chronic hepatitis
(n = 3) associated with viral hepatitis B. Seven of them also
had viral hepatitis C. During the inclusion period for this
retrospective study, there was no patient with small HCC
(≤ 2.0 cm) who was without underlying liver parenchymal
disease. The diagnosis of chronic hepatitis or cirrhosis was
made by means of histology in 50 patients and by a
combination of clinical course, blood chemistry tests
(aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, bilirubin, albumin, and globulin), and
typical CT and MRI findings in the remaining 69 patients.
Based on the Child-Pugh classification, 98 patients were
classified as Child class A, and the remaining 18 patients
were classified as class B. Liver metastases arose from the
following primary tumors: colorectal carcinoma (n = 25),
gastric carcinoma (n = 5), and pancreatic carcinoma (n = 2).
No patients with liver metastases had cirrhosis, and all had
normal hepatic function test results, including prothrombin
time and blood chemistry (serum albumin, total bilirubin
level, and choline esterase).
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All MRI examinations were performed using a 1.5 T unit
(Magnetom Symphony; Siemens, Enlargen, Germany) with
a combination of a phased array body coil for signal
reception. Baseline MR images included a respiratory-
triggered T2W-TSE sequence and a breath-hold T2*W-
GRE sequence. Respiratory-triggered T2W-TSE imaging
was obtained using the following parameters: TR/TE of
3300-4200/76, echo train length of 13, 150� flip angle,
matrix of 202 × 384, signal averages of two, and average
scan time 3 minutes. Breath-hold T2*W-GRE imaging was
obtained using the following parameters: TR/TE of 180/12,
30� flip angle, matrix of 144 × 256, signal average of one,
two sequential acquisitions, 20 slices, and average scan
time 35 seconds (two stacks with 10 slices each in a 15-17-
second breath-hold). A relatively long TE (12 ms) and
lower flip angle (30� ) were used for increasing the sensitiv-
ity to the field inhomogeneity induced by SPIO administra-
tion and for decreasing the T1 contrast, respectively (7,
13). For all sequences, a 6-7 mm slice thickness was used
with a 10% intersection gap and a field of view of 35-40
cm, depending on the size of the liver. 
In the first session, dynamic MRIs (volumetric interpo-
lated breath-hold examination, VIBE: Siemens, Erlangen,
Germany) with mSENSE were performed using the follow-
ing parameters: TR/TE of 4.3/2.0, flip angle of 12� ,
bandwidth of 450 Hz/Px, matrix of 256 (read)×135
(phase)×40-46 (partition), effective slice thickness of 3.5-
4 mm, and field of view of 32-35 cm. The determination of
scan delay for the image acquisition timing was achieved
using the test bolus technique, in which 1 mL of contrast
media was injected, followed by a 20 mL saline flush, and
the vessel of interest (the abdominal aorta) was then
scanned approximately once per second. The mean delay
time to peak aortic enhancement was 21 seconds (range:
17.0-23.0 sec). Thus, for a sequential mode of k-space
acquisition (center lines of k-space are acquired during the
middle of the acquisition time), the mean delay times (time
interval between bolus administration and the start of
image acquisition) for the early arterial, late arterial,
portal, and equilibrium phase were 20, 30, 60, and 180
seconds, respectively. The acquisition time for each phase
was 10-11 seconds. Gadopentetate dimeglumine
(Magnevist
�, Bayer HealthCare) was injected at a dosage
of 0.1 mmol/kg body weight at a rate of 2 mL/sec. The
contrast was injected into the antecubital vein using an
automated injector (Spectris MR; Medrad Europe,
Maastricht, The Netherlands), and a 20 mL saline flush
followed the contrast injection. 
In the second session, ferucarbotran (SHU-555-A;
Resovist
�, Bayer HealthCare)-enhanced imaging was
performed immediately after completion of the dynamic
MR examination. Ferucarbotran-enhanced imaging was
comprised of the respiratory-triggered T2-weighted TSE
sequence and the breath-hold T2*-weighted GRE sequence
for the baseline MRI. Patients up to 60 kg body weight
received 0.9 mL of ferucarbotran, and patients above 60
kg body weight received 1.4 mL of ferucarbotran (8-12 
mol of iron per kilogram of body weight). Ferucarbotran
was rapidly injected intravenously through a 5  m filter
and was followed by a 20 mL saline flush; imaging then
commenced approximately 10 minutes after the
intravenous injection of contrast agent. 
Imaging Analysis
Two gastrointestinal radiologists (one on-site reviewer
and one off-site reviewer), who had at least six years
experience interpreting liver imaging in their daily clinical
practice, reviewed the images independently and
separately. All images were reviewed on a 2000×2000
Picture Archiving and Communication Systems (PACS;
Marotech, Seoul, Korea) monitor. The radiologists were
aware of the overall goal of the study before the reading
session, and they knew that the patients were at risk for
HCC or metastasis, but were unaware of the presence or
location of any liver lesions or of the results of other
imaging studies. They independently reviewed three sets of
MR images in two reading sessions: (a) unenhanced T1-
and T2-weighted imaging, gadolinium-enhanced dynamic
imaging, and ferucarbotran-enhanced T2*W-GRE imaging
(the T2*W-GRE set), (b) unenhanced T1- and T2-weighted
imaging, gadolinium-enhanced dynamic imaging, and
ferucarbotran-enhanced T2W-TSE imaging (the T2W-TSE
set), and (c) a combination of the T2*W-GRE set and T2W-
TSE set (the combined set). In the first session, either the
T2*W-GRE set or the T2W-TSE set was randomly
presented with no specific patient order. In the second
session, the remaining T2*W-GRE set or T2W-TSE set was
randomly presented, and the T2*W-GRE or T2W-TSE
reviewed in the first reading recession was added for a
combined review. To minimize any learning bias, there
was at least a two-week interval between the two reading
sessions. 
The criteria for diagnosing HCC or metastasis on the
ferucarbotran-enhanced MRI were defined as a focal,
discrete, nodular high signal intensity area relative to
adjacent liver parenchyma (lower than the signal intensity
of CSF or gallbladder on a T2W-TSE sequence to exclude
the cyst) on both T2*W-GRE and T2W-TSE images. On
gadolinium-enhanced MRI, early enhancement with rapid
washout (typical of HCC) and irregular peripheral
enhancement with a peripheral washout on delayed phase
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diagnosing malignancy. For each eligible lesion, one of four
confidence levels was assigned to each decision as follows:
“1” as ‘probably not present’; “2” as ‘possibly present’;
“3” as ‘probably present’; and “4” as ‘definitely present’.
Lesions that showed only arterial hypervascularization
were regarded as category 2 if they showed no delayed
capsular enhancement, mosaic pattern, or moderate
hyperintensity on T2-weighted imaging (category 3).
During gadolinium-enhanced MRI, 115 of the total 157
HCCs showed early enhancement with rapid washout, and
the remaining 42 appeared as hyperintense nodules during
arterial phase imaging and were occult during portal and
equilibrium phase imaging. To achieve an accurate correla-
tion between the findings of the scored lesions and the
findings of the reference standard, each observer made
markings over all lesions with arrows on the PACS
monitor. After the two observers conducted the two
review sessions, the study coordinator, who was not
involved in image interpretation, compared the scoring
results of each of the observers to a gold standard, and
then a possible explanation was formulated for any false-
positive or false-negative findings. 
Statistical Analysis 
Based on the reviews submitted by the two observers, an
alternative-free response receiver operating characteristic
(ROC) curve analysis was performed on a lesion-by-lesion
basis (14). For each imaging set (T2*W-GRE images, T2W-
TSE images, and combined), an alternative-free response
ROC curve was fitted to each observer’s confidence rating
data using a maximum likelihood estimation program
(ROCKIT 0.9B; courtesy of Metz CE, University of
Chicago, IL, 1998) (15). The area under the alternative-
free response ROC curve (Az) was calculated to determine
the diagnostic accuracy of each image, each observer, and
lesion type. The differences between the imaging sets with
regard to the area under the alternative-free response ROC
curves were compared using a two-tailed Student’s t test
for paired data. The sensitivities for each image and for
each observer, as well as according to the lesion type, were
then calculated. The sensitivity was defined as the number
of true positive diagnoses, using a confidence level of 3 or
4. The sensitivities and positive predictive values for each
image set were then compared using the McNemar test. A
two-tailed p value of less than 0.05 was considered statisti-
cally significantly. We also calculated the 95% confidence
interval (CI) to determine a range of plausible sensitivity
differences. 
In order to assess interobserver agreement for evaluating
the two images and the combined approach, we calculated
the kappa statistic for multiple observers (16). Kappa
values of less than 0.20 indicated positive, but poor,
agreement, those from 0.21-0.40 indicated fair agreement,
those from 0.41-0.60 indicated moderate agreement, those
from 0.61-0.80 indicated good agreement, and those
greater than 0.81 indicated excellent agreement. 
RESULTS
For all 255 lesions, including the 157 HCCs and 98
metastases, there was a trend toward increased diagnostic
accuracy (Az values) for the combined set (mean, 0.966)
when compared with each set alone (mean, 0.892 for
T2*W-GRE set; 0.910 for T2W-TSE set), to a statistically
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Table 1. Case Distribution According to Confirmative
Diagnostic Method
HCC (n = 157) Metastasis (n = 98)
Lesion size range (mean)  0.4-2.0 cm  0.3-2.0 cm 
(mean 1.3 cm) (mean 1.1 cm)
Pathological (n = 63)
Surgery 51 45
Biopsy 12 03
Imaging study (n = 94)
MDCT (& F/U CT) & MRI 94 98
Angiography & Lipiodol CT  94
AFP (> 400 ng/ml) 10
F/U period 6 - 30 months 9 - 16 months
(mean, 18 months) (mean, 13 months)
Note.─ HCC = hepatocellular carcinoma, MDCT = multidectector CT, 
F/U = follow up, AFP = alpha fetoprotein
Table 2. Individual Accuracy (Az) for Detection of 157
Hepatocellular Carcinomas and 98 Metastases
Using T2*W GRE Set, T2W TSE Set, and Combined
Set
T2*W GRE Set T2W TSE Set Combined Set
Observer 1
All lesions 0.887  0.038  0.923  0.027 0.968  0.013 
a
HCCs 0.899  0.039 0.879  0.045  0.956  0.020 
a
Metastases 0.860  0.091 0.985  0.015 0.985  0.015
a
Observer 2
All lesions 0.896  0.036  0.897  0.034 0.964  0.015 
a
HCCs 0.883  0.044 0.871  0.047 0.954  0.021 
a
Metastases 0.929  0.052 0.941  0.044 0.980  0.019
a
Note.─ HCC = hepatocellular carcinoma, Az values are mean  1 SD.
T2*W GRE set = combining unenhanced imaging, gadolinium-enhanced
dynamic imaging, and ferucarbotran-enhanced T2*W-GRE imaging. T2W
TSE set = combining unenhanced imaging, gadolinium-enhanced
imaging, and ferucarbotran-enhanced T2W-TSE imaging. Combined set =
combining T2*W GRE set and T2W TSE set.
a Combined Az values were significantly greater than those for each
sequence alone (p < 0.05). significant degree (p = 0.004 [observer 1], 0.003 [observer
2] for the T2*W-GRE set; p = 0.033 [observer 1], 0.025
[observer 2] for the T2W-TSE set) (Table 2). Furthermore,
considering the sensitivity for all lesions, the combined set
(mean, 94.7%) was significantly more sensitive than each
set alone (mean, 86.1% for T2*W-GRE set; 87.7% for
T2W-TSE set, p = 0.0001) (Table 3).
For detection of HCCs, the Az value of the combined set
was significantly higher than that of each set alone, for
both observers (p = 0.016 [observer 1], 0.013 [observer 2]
for the T2*W-GRE set; p = 0.042 for the T2W-TSE set)
(Table 2). Although the Az values of the T2*W-GRE set
were slightly better than those of the T2W-TSE set for
both observers (Fig. 1), no significant difference was noted
for either observer (p = 0.635 for observer 1; p = 0.801 for
observer 2). Among the 157 HCCs, the T2W-TSE set
allowed for the depiction of 127 lesions (sensitivity,
80.9%; 95% CI: 73.9%, 86.7%) by observer 1 and 129
lesions (sensitivity, 82.2%; 95% CI: 75.35%, 87.8%) by
observer 2; the T2*W-GRE set allowed the depiction of
135 lesions (sensitivity, 86.0%; 95% CI: 79.6%, 91.0%)
by observer 1 and 137 lesions (sensitivity, 87.3%; 95% CI:
81.0%, 92.0%) by observer 2. There was a significant
difference in sensitivities between the two image sets for
both observers (p = 0.01). The combined approach allowed
for the depiction of 145 lesions (sensitivity, 92.4%; 95%
CI: 87.05%, 96.0%) by observer 1 and 147 lesions
(sensitivity, 93.6%; 95% CI: 88.6%, 96.9%) by observer 2
Kim et al.
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AB
Fig. 1. 55-year-old man with well-differentiated hepatocellular carcinoma in subcapsular area of right hepatic lobe.
A. Axial respiratory-triggered T2-weighted turbo spin echo (4200/76) imaging shows no hepatic mass.
B. Axial arterial phase three-dimensional dynamic MRI after administration of gadopentetate dimeglumine (4.3/2.0) shows no detected
lesion.
C. Axial ferucarbotran-enhanced breath-hold T2*-weighted gradient echo imaging (180/12) shows high signal intensity nodule (arrow) in
subcapsular area of liver, which was assigned confidence level of 4 by both observers.
D. Axial ferucarbotran-enhanced respiratory-triggered T2-weighted turbo spin echo imaging (4200/76) shows no definitive lesion (arrow)
at same location as in A. This was assigned score of 1 and 2 by the two observers, respectively. 
CD(mean, 93.0%), which was significantly better than the
values obtained using each set alone (mean, 81.6% for
T2W-TSE set, 86.7% for T2*W-GRE set) (p = 0.0001 for
T2W-TSE set, p = 0.002 for T2*W-GRE set). There were
nine and eight HCCs (size range: 0.6-1.2 cm, mean size:
0.9 cm) for each observer, respectively, which were not
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AB
Fig. 2. 50-year-old man with two hepatocellular carcinomas in right
hepatic lobe.
A. Axial arterial phase three-dimensional dynamic MRI after
administration of gadopentetate dimeglumine (4.3/2.0) shows
subtle small nodular enhancement (arrow) in subcapsular area of
right hepatic lobe. Inferior margin of main mass located at slightly
higher level is shown (small arrows).
B. Axial ferucarbotran-enhanced breath-hold T2*-weighted
gradient echo imaging (180/12) shows only main mass (arrows) in
posterior portion of right hepatic lobe. Subcapsular lesion was
assigned score of 1 by both observers using T2*-weighted gradient
echo image set.
C. Axial ferucarbotran-enhanced respiratory-triggered T2-weighted
turbo spin echo imaging (4200/76) shows definitive round hyperin-
tense subcapsular mass (arrow) and main mass (small arrows),
which were assigned confidence level of 4 by both observers.
C
Table 3. Sensitivities and Positive Predictive Values for Revealing 157 Hepatocellular Carcinomas and 98 Metastases Using
T2*W GRE Set, T2W TSE Set, and Combined Set
T2*W GRE Set T2W TSE Set Combined Set
Sensitivity PPV Sensitivity PPV Sensitivity PPV
Observer 1
All lesions 85.5% (218) 98.6% [3] 87.5% (223) 99.6% [1] 94.5% (241) 
a 99.6% [1]
HCCs 86.0% (135) 
b 98.5% [2] 80.9% (127) 
b 99.2% [1] 92.4% (145) 
a 99.3% [1]
Metastases 84.7% (83)  98.8% [1] 98.0% (96) 
c 100.0% [0] 98.0% (96) 
c 100.0% [0]
Observer 2
All lesions 86.7% (221) 98.6% [3] 87.8% (224) 98.7% [3] 94.9% (242) 
a 99.6% [1]
HCCs 87.3% (137) 
b 97.9% [3] 82.2% (129) 
b 98.5% [2] 93.6% (147) 
a 99.3% [1]
Metastases 85.7% (84)  100.0% [0] 96.9% (95) 
c 99.0% [1] 96.9% (95) 
c 100.0% [0]
Note.─ Numbers in parentheses and brackets represent number of both true- and false-positive lesions, respectively. 
HCC = hepatocellular carcinoma, PPV = positive predictive value. T2*W GRE set = combining unenhanced imaging, gadolinium-enhanced dynamic
imaging, and ferucarbotran-enhanced T2*W-GRE imaging. T2W TSE set = combining unenhanced imaging, gadolinium-enhanced imaging, and
ferucarbotran-enhanced T2W-TSE imaging. Combined set = combining T2*W GRE set and T2W TSE set.
a Sensitivity was significantly greater than that for each sequence alone (p < 0.05).
b There was significant difference between sensitivities of two sequences (p < 0.05).
c Sensitivity was significantly greater than that for T2*W-GRE image (p < 0.05).detected on the T2*W-GRE set, but which were detected
on the T2W-TSE set (Fig. 2). There were 17 HCCs (size
range: 0.6-1.9 cm, mean size: 1.2 cm) for both observers
that were not detected on the T2W-TSE set, but which
were detected on the T2*W-GRE set. Of the 51 HCCs with
surgical confirmation, four well-differentiated HCCs were
not detected by either observer on the T2W-TSE set, but
were detected on the T2*W-GRE set by both observers.
For the remaining lesions, the two image sets showed
similar results. 
For the detection of liver metastases, the Az values of
the combined set and the T2W-TSE set were better than
those of the T2*W-GRE set for both observers, although
the difference was not statistically significant (p = 0.134 for
observer 1; p = 0.162, 0.772 for observer 2). The sensitiv-
ity of the combined set was the same as that of the T2W-
TSE set (98.0%; 95% CI: 92.8%, 99.7%, for observer 1;
96.9%; 95% CI: 91.3%, 99.3%, for observer 2; mean
97.5%), which was significantly better than that of the
T2*W-GRE set for both observers (84.7%; 95% CI:
76.0%, 91.2%, for observer 1; 85.7%; 95% CI: 77.2%,
92.0%, for observer 2; mean 85.2%) (p = 0.0001) (Fig. 3).
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Fig. 3. 57-year-old man with surgically confirmed 0.4-cm liver metastasis from rectal cancer.
A. Axial ferucarbotran-enhanced breath-hold T2*-weighted gradient echo imaging (180/12) shows irregular high signal intensity lesion
(arrow) at medial margin of right hepatic lobe, which was missed by one observer and was assigned confidence level of 2 by other
observer during image interpretation.
B. Axial ferucarbotran-enhanced respiratory-triggered T2-weighted turbo spin echo imaging (4200/76) clearly shows small round
hyperintense mass (arrow) at same location as in A. This was assigned score of 4 by both observers.
AB
Fig. 4. 55-year-old man with surgically confirmed 0.4-cm liver metastasis from colon cancer.
A. Axial ferucarbotran-enhanced breath-hold T2*-weighted gradient echo imaging (180/12) shows irregular high signal intensity lesion
(arrow) in inferior portion of right hepatic lobe. Both reviewers missed this lesion during image interpretation.
B. Axial ferucarbotran-enhanced respiratory-triggered T2-weighted turbo spin echo imaging (4200/76) clearly shows small round
hyperintense mass (arrow) at same location as in A. This was assigned score of 3 by both observers.
ABThere were 11 metastases (0.4-0.8 cm) that were not
detected by either observer on the T2*W-GRE set, but
which were clearly revealed on the T2W-TSE set (Fig. 4).
However, there was no lesion detected on the T2*W-GRE
set that could not be verified on the T2W-TSE set. 
Each image set showed a similar positive predictive
value for each observer (Table 3). Both observers had six
false-positive findings on the T2*W-GRE set, four false-
positive findings on the T2W-TSE set, and two false-
positive findings on the combined set. All false-positive
findings were attributed to the end-on of vessels or fibrosis
in the case of cirrhotic patients. The kappa values for the
two observers were 0.746 for the T2*W-GRE set, 0.762
for the T2W-TSE set, and 0.685 for the combined set,
indicating good inter-observer agreement with regard to
the presence of lesions. 
DISCUSSION
T2*W-GRE and T2W-TSE are techniques mainly used
with SPIO-enhancement (7-10). T2*W-GRE in SPIO
enhancement provides the highest lesion to liver contrast
because of its strong magnetic susceptibility resulting from
local field inhomogeneity (7, 8), but it suffers from low
signal-to-noise ratio (SNR) and has poor pre-contrast image
quality. Furthermore, T2*W-GRE might be limited in
advanced cirrhotic livers because the decrease in signal
intensity of cirrhotic livers on T2*W-GRE sequences is less
pronounced than on T2W-TSE sequences (17). Meanwhile,
the respiratory-triggered T2W-TSE sequence offers higher
spatial resolution because of its large image matrices, less
blooming effect because of the robustness of the T2*
effect, and preferable T2-weighted image contrast; small
rounded areas of hyperintensity caused by hepatic cysts or
hepatic vessels are efficiently differentiated from small
malignant tumors (18). However, TSE is less sensitive to
SPIO, probably because of increased magnetization
transfer saturation and decreased susceptibility effects due
to the use of multiple 180� refocusing pulses (19).
Furthermore, image degradation from motion artifact
could be severe on TSE. In the present study, we hypothe-
sized that combining SPIO-enhanced T2*W-GRE and
T2W-TSE sequences had additive value compared to each
sequence alone for the detection of small liver malignan-
cies, including HCCs and metastases, due to these theoreti-
cal relative advantages and disadvantages of T2*W-GRE
and T2W-TSE sequences. 
Our study showed that there was a trend toward
increased Az values for the combined approach compared
to each image set alone. Regarding the sensitivities for the
detection of HCCs, the combined approach was signifi-
cantly better than each image set alone (p < 0.05), and the
T2*W-GRE set was better than the T2W-TSE set for both
observers (p < 0.05). The higher detectability of T2*W-
GRE for HCC could be explained by its higher inherent
lesion to liver contrast and possible inclusion of well differ-
entiated HCCs in study cases; most lesions included in this
study were 2 cm or smaller (17, 20). Tanimoto et al. (17,
20) showed that relative post-SPIO-enhanced SNR changes
in the liver parenchyma between cirrhotic and non-
cirrhotic patients were remarkable on the T2*W-GRE
sequence, but not on the T2W-TSE sequence. They
claimed that small intracellular SPIO clusters caused by
decreased Kupffer cell function in cirrhosis caused little
SNR drop in the liver parenchyma on the T2*W-GRE
sequence compared to the T2W-TSE sequence, because
SNR loss on the magnetic susceptibility-insensitive T2W-
TSE sequence is related to the greater free water interac-
tion made possible by the relatively larger surface area of
the small SPIO clusters (20). However, given that Kupffer
cells density in well-differentiated HCCs would be
maintained, but Kupffer cells function would be reduced
compared to the surrounding liver, small intracellular SPIO
clusters in well-differentiated HCCs also produce little
SNR decrease on the T2*W-GRE sequence, which could
result in better lesion conspicuity than on the T2W-TSE
sequence (21). Of the 51 HCCs in our study with surgical
confirmation, four lesions were not detected by either
observer on the T2W-TSE set, but were detected on the
T2*W-GRE set by both observers. All four lesions proved
to be well-differentiated HCCs.
With regard to the detection of metastases that do not
contain Kupffer cells, the sensitivity of the combined
approach was the same as that of the T2W-TSE set, which
was significantly better than that of the T2*W-GRE set for
both observers. Despite the higher inherent lesion to liver
contrast on the T2*W-GRE, the better detection capability
of the T2W-TSE for metastases could be explained by
signal loss caused by a magnetization transfer effect, with
the TSE sequence being lower in metastases than in HCC
because tumor necrosis and abundant interstitial space in
metastases generally contain more abundant free water
compared with HCC (22, 23). There were 11 metastases
(0.4-0.8 cm) that were not detected by either observer on
the T2*W-GRE set, but which were clearly revealed on the
T2W-TSE set. When we retrospectively reviewed these
lesions on the T2*W-GRE image, all were depicted as tiny
high signal intensities with irregular margins, and some
small lesions were abutted on intrahepatic venous
structures. These lesions were difficult to differentiate from
the end-on of the vessel because vessels are depicted with
bright hyperintensity, as is true malignancy on the T2*W-
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able to an exaggerated T2*-shortening effect on the T2*W-
GRE sequence, which has a relatively long TE (12 ms), that
may have partially obscured the margins of the smaller
liver lesions, especially those located at the dome abutting
the lung or the left hepatic lobe abutting the gastric lumen
(13). Moreover, the relatively lower spatial resolution of
the T2*W-GRE sequence (144 × 256) compared to the
T2W-TSE sequence (202 × 384) and the inherent blurring
of high signal intensity structures on the T2*W-GRE
sequence may also be behind this phenomenon. In addition
to the shortcomings of the T2*W-GRE sequence in
advanced cirrhotic livers, these could also explain the nine
and eight HCCs detected only on the T2W-TSE set, but
not on the T2*W-GRE set, by observers 1 and 2, respec-
tively. 
There are several limitations to our study. First, not all
lesions were surgically confirmed, which could have
resulted in overestimation of the sensitivity of each image
by reducing false-negative lesions. However, our study was
not intended to determine the absolute diagnostic accuracy
and sensitivity of the MR sequence, but to determine the
relative diagnostic efficacy of combined MR sequences
compared to single sequences for the detection of liver
malignancy. Furthermore, the relatively thick slice
thickness (0.6 or 0.7 cm) of ferucarbotran-enhanced MR
sequences is inherently limiting in the detection of small
hepatic tumors. A second limitation is that a quantitative
analysis to determine the conspicuity of HCC according to
the histologic differentiation or the number of Kupffer cells
was not made. In addition, quantitative analysis was not
done regarding the tumor-to-liver contrast. However,
optimal contrast-to-noise ratio does not necessarily
translate into better detecting capability (24). In this
regard, the 12 ms TE for the T2*W-GRE sequence used in
our protocol might be slightly long to obscure the margin
of small hyperintense nodules (13). HCCs only detected on
the T2W-TSE set (mean size, 0.9 cm) tended to be smaller
than those only detected on the T2*W-GRE set (mean size,
1.2 cm). Additionally, since the image quality of the liver
was higher with the respiratory-triggered TSE sequence
owing to its large image matrices, exact direct comparison
between the two sequences in this study could not be
made. In our study, the diagnostic accuracy of the
combined set for metastases was slightly better than that
for each image set for observer 2. Although diagnostic
confidence is a subjective parameter that cannot be
directly translated into diagnostic performance, such as
sensitivity, an increase in physician confidence might
contribute significantly to patient management. Therefore,
considering the higher inherent lesion to liver contrast of
T2*W-GRE in SPIO enhancement, we believe that the
T2*W-GRE sequence has the potential to provide an
additional role for T2W-TSE in the detection of metastases.
Third, the results of this study do not necessarily reflect the
pure diagnostic capabilities of SPIO-enhanced images for
the detection of HCC, because we included an analysis of
all sequences combined. Lastly, differences in the MR
imager, MR parameters, and methods for image review
used may result in different results. Therefore, the results
of this study might not be able to be extrapolated to other
facilities with different MR imagers or sequences.
Additionally, we did not evaluate other commercially used
sequences for SPIO-enhanced MRI in this study (19). 
In conclusion, a combination of ferucarbotran-enhanced
T2*W-GRE and T2W-TSE images in combining gadolinium
and ferucarbotran-enhanced MRI had better diagnostic
capability compared to each sequence alone for the
detection of HCC in cirrhotic patients. No difference in
sensitivity for the detection of metastases was noted
between the T2W-TSE set and the combined T2*W-
GRE/T2W-TSE set, suggesting that the respiratory
triggered T2W-TSE sequence in ferucarbotran-enhanced
MRI is preferred for the detection of small liver metastases
in non-cirrhotic patients. 
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